LifeMax Partnering

LifeMax has built up its portfolio through partnering with both pharma/biotech companies and academic institutions. Focusing on orphan diseases with few or no approved options, we continue to look for partnering opportunities, via licensing, acquisition or research collaboration. We are interested in all modalities and first-in-class or best-in-class assets that target the underlying genetic deficiency.

LifeMax licensed the worldwide right to BPR277, now LM-030 in development for Netherton Syndrome.

AmMax Licensed the worldwide right to AMG 820, now AMB-051 in development for Tenosynovial Giant Cell Tumor. The same molecule is also being developed for Idiopathic Pulmonary Fibrosis (AMB-053) and Polycystic Kidney Disease (AMB-055).

Treating Orphan Diseases With Few or No Options.


Redwood City, CA, USA


Taipei, Taiwan